Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Revenue of Kymera Therapeutics, Inc. (KYMR)
Revenue in 2023 (TTM): $78.59 M
According to Kymera Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $78.59 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Kymera Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $78.59 M | $75.03 M | $-143,201,000 | $-146,962,000 | $-146,962,000 |
| 2022 | $46.83 M | $43.85 M | $-154,632,000 | $-154,808,000 | $-151,831,000 |
| 2021 | $72.83 M | $70.44 M | $-100,042,000 | $-100,217,000 | $-97,995,000 |
| 2020 | $34.03 M | $-28,071,000 | $-45,478,000 | $-45,593,000 | $-43,945,000 |
| 2019 | $2.93 M | $2.11 M | $-40,375,000 | $-41,246,000 | $-41,292,000 |
| 2018 | $ | $-205,000 | $-21,246,000 | $-21,467,000 | $-21,467,000 |